Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA 90502, USA.
Dermatol Clin. 2011 Jan;29(1):89-102. doi: 10.1016/j.det.2010.08.014.
Despite the ubiquity and severity of parasitic diseases and our desire to prevent them, there are no effective antiparasitic vaccines in widespread clinical use. This review focuses on strategies for development of a vaccine against cutaneous leishmaniasis as a representative parasitic disease of paramount interest to dermatologists and all who care for patients who live in or travel to the developing world. Any effective strategy will require attention to the central role that host innate immunity plays during induction of durable resistance to these virulent protozoa. The cell types, receptors, and molecules of the innate immune system that will likely play a role in any effective vaccine against cutaneous leishmaniasis are reviewed.
尽管寄生虫病普遍存在且严重,我们也希望加以预防,但目前仍没有广泛应用于临床的有效抗寄生虫疫苗。本综述以利什曼原虫病疫苗的开发策略为重点,利什曼原虫病是一种具有代表性的寄生虫病,皮肤科医生以及所有关注生活在或前往发展中国家的患者的人都对此高度关注。任何有效的策略都需要关注宿主固有免疫在诱导对这些毒力原生动物的持久抗性中的核心作用。本文回顾了固有免疫系统的细胞类型、受体和分子,它们可能在任何有效的抗皮肤利什曼病疫苗中发挥作用。